A patient-count milestone is the least glamorous number in medical travel and usually one of the more useful ones. On 3 November 2026, China News Service's Shanghai channel reported that 上海市质子重离子医院, Shanghai's proton and heavy ion hospital, had passed 10,000 patients treated and discharged after 11.5 years of formal operation, citing a five-year overall survival rate of 70.4% and describing the results as internationally advanced. For international patients comparing proton therapy in China with centres in Japan, Germany or Thailand, the interesting part is not the promotional framing. It is that cumulative treated volume is one of the few variables that maps directly onto the questions you actually have: has this team planned enough courses for your tumour site to anticipate your anatomy, and has it managed enough complications to notice yours early?
Why a case count matters more than a machine specification
Particle therapy is not delivered by equipment. It is delivered by a workflow: simulation imaging, target and organ-at-risk delineation, plan review by a second physicist or physician, daily image guidance, and the judgement calls made when a patient loses weight mid-course or a tumour shrinks. Each of those steps is where outcome differences between high-volume and low-volume programmes tend to appear.
What "10,000 cases" buys that a brochure cannot
Two things follow from accumulated volume specifically.
The first is position on the learning curve. A centre that has completed more than ten thousand courses has, as a matter of arithmetic, passed the phase where rare anatomies and unusual toxicities are surprises. That does not guarantee better results for any individual patient; it means the probability that your case resembles something the team has already solved is higher.
The second is a documented indication range. The report states the centre treats more than 50 malignant tumour types. A programme that publishes a wide case mix and still reports volume in each of several groups — 5,139 head and neck cases, 3,192 abdominal and pelvic cases, 1,669 thoracic cases — is making itself auditable in a way a single-disease programme is not. When you ask "how many patients like me have you treated," a broad, itemised caseload is the answer that lets you say something meaningful.
What proton therapy in China's volume figures can and cannot tell you
Everything quotable in this article comes from the 3 November report: 11.5 years of operation, more than 10,000 patients treated and discharged, 70.4% five-year overall survival, coverage of 50-plus tumour types, and the site-level counts above. The same report contrasts those years with roughly 15 years for a comparable German institution and more than 20 years in Japan to reach the ten-thousand mark.
What the figures support is a claim about experience and breadth. What they do not support is a claim about your odds.
- A five-year overall survival figure for a mixed cohort averages paediatric and adult, early-stage and locally advanced, previously untreated and previously irradiated patients. It is not a prediction, and it is not comparable line-for-line with another country's published number, because referral patterns and selection criteria differ.
- Cumulative volume says nothing about current access. Slots, waiting periods and bed availability are set by the centre's own schedule at the time of your review, and the report does not address them.
- "Internationally advanced" is the report's characterisation, not an independent benchmark. Ask any centre you shortlist which audit or registry its outcomes are submitted to.
- Costs are not published in the report. Treatment price is set by the centre's quotation after your medical file has been reviewed; third-party figures circulated online should be treated as estimates only, and confirmed against the official quote.
A specific treatment plan — whether particle therapy is appropriate at all, and which beam modality — must be assessed by a licensed physician who has reviewed your imaging and pathology, in person or through formal remote review.
Comparing Shanghai with Japan, Germany and Thailand on what is checkable
| Destination | Time to 10,000 treated patients, per the Shanghai report | Site-level volume you can ask for | What to verify before you commit |
|---|---|---|---|
| China (Shanghai) | 11.5 years of operation | Head and neck 5,139; abdominal/pelvic 3,192; thoracic 1,669; 50+ tumour types overall | Your own site's case count, current scheduling window, written quotation, and who provides translated documentation |
| Germany | ~15 years for the comparable institution cited | Not covered in our sourcing | Whether your indication is within the centre's published list, and whether a slot can be timed to your travel window |
| Japan | 20+ years for the comparable institution cited | Not covered in our sourcing | Language support during planning imaging, and whether overseas patients are accepted for a full course or only a fraction of it |
| Thailand | No figure in our sourcing | Not covered in our sourcing | Whether a full particle course is delivered locally, or whether the plan involves referral elsewhere |
The empty cells are deliberate. This article only quotes figures we have verified, and the useful habit when comparing is to notice which destinations a volume story cannot be told about without asking them directly. If you want the broader context on how Chinese particle therapy programmes are organised and how they are reached, our proton therapy China guide and the proton and heavy ion service page cover the practical side.
Where the volume data is most relevant to you
The two largest groups in the report — head and neck, and abdominal and pelvic — happen to be the sites where sparing normal tissue drives quality of life most directly. In head and neck tumours, the dose-limiting structures are salivary glands, swallowing musculature, the optic apparatus and temporal lobes; plan quality determines whether a patient leaves treatment with permanent dry mouth or swallowing difficulty. In pelvic and abdominal disease, bowel and bladder motion between fractions is the central planning problem, and motion management is a team skill more than a machine feature. Thoracic cases add their own variable: tumour and organ movement with respiration.
If your diagnosis falls into one of these groups, ask specifically how many patients with that site and stage the centre has planned, and how motion management and image guidance are performed day to day. The aggregate number is context; the site-level number is what you are buying.
If your disease is primarily haematological, particle radiotherapy may simply be the wrong question — see CAR-T therapy in China for a different pathway and what its eligibility rules involve.
Planning the actual course: sequence, not promises
A full course of fractionated particle therapy is a logistics problem as much as a clinical one. The order is broadly fixed even when the dates are not:
- Submission of pathology, imaging (original DICOM, not only reports or films), prior treatment records and operative notes for physician review.
- A formal indication decision — whether particle therapy is appropriate, and proton or heavy ion.
- A written quotation and payment terms, followed by scheduling of simulation and treatment planning.
- Arrival for simulation, plan approval, then daily fractions over several weeks, which usually means arranging accommodation near the centre for the entire course.
- Discharge documentation, a summary report, and a plan for reporting toxicity after you have gone home.
Only step 2 has a clinical answer, and only the centre can date the rest. Plan your visa and travel after, not before, an indication decision exists — the medical visa guide explains the documentation that typically accompanies a treatment invitation, and the Shanghai hospital appointment service covers the scheduling step for patients who need help getting file review booked.
The new companion-care standard gives foreign patients something checkable
International patients in China rarely navigate specialist clinics, cross-department registration, examinations, pharmacy collection and record translation alone; they depend on accompany-care or coordination staff. On 1 November 2026, the first unified national standard in this field, GB/T 47801—2026,《社会化陪同就医服务基本要求》, took effect. As reported, it requires accompanying personnel to complete professional training and hold a qualifying certificate before working independently, with training covering basic medical knowledge, the visit workflow, communication, and emergency handling.
That gives you a short, verifiable checklist when you arrange support for a treatment course:
- Ask to see the training completion or qualification evidence for the specific person, not a marketing claim about the agency.
- Confirm whether the person can handle multi-language陪同 across departments, or only escort you to a counter.
- Ask what the emergency procedure is and who is called first, since the standard's training scope includes emergency handling.
- Get the scope in writing: registration, accompaniment, medication collection, report translation, follow-up coordination — priced separately or bundled.
- Ask whether translated documents are prepared by the companion or by the hospital, and whether they are usable for a second opinion at home.
A standard does not certify any individual provider. It does move the conversation from "trust us" to "show me," which is the point.
When volume should reassure you, and when it should not
Reasons the Shanghai figures are genuinely relevant to a decision: your tumour site is among the three groups with itemised counts; the centre states a 50-plus indication list rather than a narrow menu; and 11.5 years of continuous operation means the reporting period is long enough that rare complications would have appeared somewhere.
Reasons to slow down anyway: you have been told you are eligible without anyone reviewing original DICOM imaging; the indication decision comes from a broker rather than a physician; costs are quoted as a round number before file review; or no one can describe how late toxicity is followed once you have left the country. Ask for the second opinion pathway in writing, and compare it against what other centres offer in our overview of cancer treatment in China.
Getting your file reviewed before you choose a country
OriEast reviews your pathology and imaging with the receiving hospital, arranges the physician consult, handles translation, registration and day-to-day coordination during treatment, and helps you line up compliant accompany-care staff under the new standard. Start with a case evaluation so a physician — not a brochure — decides whether particle therapy applies to you, or send your questions through the inquiry form. Either way, the question to put to every centre on your shortlist is the same one this milestone makes easy to ask: how many patients like me have you actually treated, and when can you see me.